.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,863,249

« Back to Dashboard

Claims for Patent: 7,863,249

Title:Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile ("C. difficile"), Clostridium perfringens ("C. perfringens"), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
Inventor(s): Chiu; Yu-Hung (San Diego, CA), Che; Tessie Mary (San Diego, CA), Romero; Alex (San Diego, CA), Ichikawa; Yoshi (San Diego, CA), Shue; Youe-Kong (Carlsbad, CA)
Assignee: Optimer Pharmaceuticals, Inc. (San Diego, CA)
Application Number:12/101,552
Patent Claims: 1. A pharmaceutical composition comprising a therapeutically effective amount of a polymorphic form of a compound of Formula I: ##STR00010## wherein the polymorphic form of a compound of Formula I is characterized by a powder x-ray diffraction pattern wherein said x-ray diffraction pattern comprises peaks at diffraction angles 2.theta. of 7.7.degree., 15.0.degree., and 18.8.degree..+-.0.2 as said peaks are set forth in FIG. 1.

2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of a polymorphic form of a compound of Formula I comprises about 0.001 mg to about 1000 mg.

3. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of a polymorphic form of a compound of Formula I comprises about 0.01 mg to about 500 mg.

4. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of a polymorphic form of a compound of Formula I comprises about 0.1 mg to about 100 mg.

5. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of a polymorphic form of a compound of Formula I comprises about 0.5 mg to about 50 mg.

6. The pharmaceutical composition of claim 1 suitable for oral administration.

7. The pharmaceutical composition of claim 1 suitable for topical administration.

8. The pharmaceutical composition of claim 1, wherein the polymorphic form of a compound of Formula I is a lyophilized powder.

9. The pharmaceutical composition of claim 8, further comprising a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is characterized by a DSC endotherm in the range of about 174.degree. C. to about 186.degree. C.

11. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is characterized by: (i) a powder x-ray diffraction pattern wherein said x-ray diffraction pattern comprises peaks at diffraction angles 2.theta. of 7.7.degree., 15.0.degree., and 18.8.degree..+-.0.2 as said peaks are set forth in FIG. 1; and (ii) a DSC endotherm in the range of about 174.degree. C. to about 186.degree. C.

12. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is characterized by a powder X-ray diffraction pattern as set forth in FIG. 1.

13. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in about 75 wt. % to about 99.99 wt. %.

14. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in at least about 85 wt. %.

15. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in at least about 90 wt. %.

16. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in at least about 95 wt. %.

17. The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in at least about 99 wt. %.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc